Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 16Urinary Bladder Neoplasms 15Carcinoma, Merkel Cell 10Neoplasm Metastasis 8Carcinoma, Renal Cell 8Breast Neoplasms 8Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Ureteral Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urethral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Neuroendocrine Tumors 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Urothelial Cancer 1Turcot syndrome 1Thymoma 1

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Cancer × avelumab × 1 year × Clear all
NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡